MCID: SPN186
MIFTS: 66

Spinal Cord Injury

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Cord Injury

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 39 77 55 60 17
Spinal Cord Injuries 44

Characteristics:

Orphanet epidemiological data:

60
spinal cord injury
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

ICD10 via Orphanet 35 T09.3
UMLS via Orphanet 75 C0037929
Orphanet 60 ORPHA90058

Summaries for Spinal Cord Injury

MedlinePlus : 44 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to brain injury and traumatic brain injury. An important gene associated with Spinal Cord Injury is RTN4IP1 (Reticulon 4 Interacting Protein 1), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and PEDF Induced Signaling. The drugs Pregabalin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

NINDS : 55 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 77 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Related Diseases for Spinal Cord Injury

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 brain injury 31.2 BDNF CASP3 GFAP IL6
2 traumatic brain injury 30.9 AQP4 BDNF CASP3 GFAP IL6
3 osteomyelitis 30.5 CXCL8 IL6 TNF
4 prostatitis 30.5 CXCL8 IL6 TNF
5 colitis 30.4 CXCL8 IL6 NOS2 TNF
6 disease of mental health 30.4 BDNF IL6 PDYN
7 acute respiratory distress syndrome 30.4 CXCL8 IL6 TNF
8 myelitis 30.4 AQP4 IL6 TNF
9 fasciitis 30.3 CXCL8 IL6 TNF
10 pyelonephritis 30.2 CXCL8 IL6 TNF
11 multiple sclerosis 30.2 AQP4 BDNF GFAP IL6 MMP9 NOS2
12 spinal cord disease 30.2 AQP4 GDNF IL6 TNF
13 arteries, anomalies of 30.1 IL6 LEP MMP9 TNF
14 end stage renal failure 30.1 IL6 LEP TNF
15 crohn's colitis 30.1 CXCL8 NOS2 TNF
16 endocarditis 30.0 CXCL8 IL6 TNF
17 acute pancreatitis 29.8 CXCL8 IL6 PLA2G2A
18 liver disease 29.8 CASP3 IL6 LEP TNF
19 peripheral nervous system disease 29.6 AQP4 IL6 TNF
20 transverse myelitis 29.6 AQP4 CXCL8 IL6 MMP9 TNF
21 vascular disease 29.5 IL6 MAPK1 MMP9 NOS2 TNF
22 amyotrophic lateral sclerosis 1 29.5 BDNF CASP3 GDNF GFAP NGFR NOS1
23 fatty liver disease 29.4 CASP3 CXCL8 IL6 LEP TNF
24 alzheimer disease 28.8 BDNF CASP3 GDNF GFAP MAPK1 NGFR
25 respiratory failure 11.7
26 spasticity 11.6
27 central cord syndrome 11.6
28 paraplegia 11.5
29 neurogenic bowel 11.5
30 acute cystitis 11.5
31 syringomyelia 11.5
32 spinal shock 11.4
33 myoclonus 11.4
34 tethered cord syndrome 11.4
35 swallowing disorders 11.4
36 tethered spinal cord syndrome 11.1
37 central cervical cord syndrome 11.1
38 neurogenic bladder 10.7
39 decubitus ulcer 10.7
40 depression 10.6
41 pain - chronic 10.6
42 quadriplegia 10.5
43 impotence 10.5
44 bacteriuria 10.5
45 detrusor sphincter dyssynergia 10.5
46 pure autonomic failure 10.5
47 scorpion envenomation 10.4 IL6 TNF
48 infertility 10.4
49 anxiety 10.4
50 thrombosis 10.4

Graphical network of the top 20 diseases related to Spinal Cord Injury:



Diseases related to Spinal Cord Injury

Symptoms & Phenotypes for Spinal Cord Injury

GenomeRNAi Phenotypes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP3 CXCL8 GDNF NGFR NOS2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CASP3 CXCL8 GDNF MAPK1 NGFR NOS2

MGI Mouse Phenotypes related to Spinal Cord Injury:

47 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 AQP4 BDNF CASP3 GDNF GFAP IL6
2 digestive/alimentary MP:0005381 10.42 AQP4 BDNF CASP3 GDNF GFAP IL6
3 homeostasis/metabolism MP:0005376 10.41 AQP4 BDNF CASP3 GFAP IL6 KLK8
4 cellular MP:0005384 10.4 BDNF CASP3 GDNF GFAP IL6 LEP
5 growth/size/body region MP:0005378 10.4 AQP4 BDNF CASP3 GDNF GFAP IL6
6 cardiovascular system MP:0005385 10.37 AQP4 CASP3 GDNF GFAP IL6 LEP
7 nervous system MP:0003631 10.34 AQP4 BDNF CASP3 GDNF GFAP IL6
8 mortality/aging MP:0010768 10.32 AQP4 BDNF CASP3 GDNF GFAP IL6
9 immune system MP:0005387 10.3 AQP4 CASP3 GDNF GFAP IL6 LEP
10 hematopoietic system MP:0005397 10.29 AQP4 CASP3 GDNF IL6 LEP MAPK1
11 endocrine/exocrine gland MP:0005379 10.27 AQP4 BDNF CASP3 GDNF IL6 LEP
12 integument MP:0010771 10.21 BDNF CASP3 IL6 LEP MAPK1 MMP9
13 muscle MP:0005369 10.2 CASP3 GDNF GFAP IL6 LEP MAPK1
14 adipose tissue MP:0005375 10.15 IL6 LEP NGFR NOS1 NOS2 PDYN
15 liver/biliary system MP:0005370 10.04 IL6 LEP MAPK1 NGFR NOS1 NOS2
16 renal/urinary system MP:0005367 10.02 AQP4 CASP3 GDNF IL6 LEP MMP9
17 reproductive system MP:0005389 10.02 BDNF CASP3 GDNF IL6 LEP MAPK1
18 respiratory system MP:0005388 10 AQP4 BDNF CASP3 IL6 LEP MAPK1
19 no phenotypic analysis MP:0003012 9.95 AQP4 BDNF CASP3 NOS1 PDYN RTN4R
20 skeleton MP:0005390 9.85 CASP3 IL6 LEP MAPK1 MMP9 NGFR
21 vision/eye MP:0005391 9.4 AQP4 BDNF CASP3 GFAP IL6 LEP
22 taste/olfaction MP:0005394 9.26 BDNF CASP3 MAPK1 NGFR

Drugs & Therapeutics for Spinal Cord Injury

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 450)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
2
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1401-55-4
3
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
4
Sodium Citrate Approved, Investigational Phase 4,Not Applicable 68-04-2
5
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
6
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
7
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
8
Baclofen Approved Phase 4,Phase 2,Not Applicable 1134-47-0 2284
9
Dopamine Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
10
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
11
Amitriptyline Approved Phase 4 50-48-6 2160
12
Perphenazine Approved Phase 4 58-39-9 4748
13
Teriparatide Approved, Investigational Phase 4,Phase 2 52232-67-4 16133850
14
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
15
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
16
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
17
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
18
Neostigmine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-99-4 4456
19
Darifenacin Approved, Investigational Phase 4,Phase 2 133099-04-4 444031
20
Oxcarbazepine Approved Phase 4 28721-07-5 34312
21
Midodrine Approved Phase 4,Phase 3,Phase 2 133163-28-7, 42794-76-3 4195
22
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
23
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
24
Dextromethorphan Approved Phase 4,Phase 2 125-71-3 5362449 5360696
25
Droxidopa Approved, Investigational Phase 4,Phase 1 23651-95-8 443940
26
Cycloserine Approved Phase 4,Early Phase 1 68-41-7 6234 401
27
Denosumab Approved Phase 4 615258-40-7
28
Trazodone Approved, Investigational Phase 4,Phase 2 19794-93-5 5533
29
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
30
Glucagon Approved Phase 4 16941-32-5
31
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
32
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
33
Vancomycin Approved Phase 4 1404-90-6 14969 441141
34
Fidaxomicin Approved Phase 4 873857-62-6
35
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
36
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
37
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
38
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
39
Serine Approved, Nutraceutical Phase 4,Phase 2,Phase 3 56-45-1 5951
40
Lactitol Investigational Phase 4 585-88-6, 585-86-4 493591
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
45 calcium channel blockers Phase 4,Phase 3,Not Applicable
46 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
47 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
48 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
50 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 1177)
# Name Status NCT ID Phase Drugs
1 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
2 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
3 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
4 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
5 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
7 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
8 Bowel Care and Cardiovascular Function After Spinal Cord Injury Completed NCT01567605 Phase 4 Lidocaine lubricant
9 Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males Completed NCT01067391 Phase 4 tadalafil;placebo
10 Assess Efficacy in Subjects With Traumatic Spinal Cord Injury Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
11 Chronic Pain in Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
12 Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
13 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
14 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) Completed NCT00826228 Phase 4 teriparatide
15 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
16 Pressure Ulcer Healing With Microcyn Completed NCT02001558 Phase 4 Microcyn
17 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
18 A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
19 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury Completed NCT00286520 Phase 4
20 Zoledronic Acid Administration in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
21 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed NCT00745095 Phase 4 Neostigmine
22 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
23 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
24 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
25 Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels Completed NCT01896037 Phase 4
26 Symptom Based Treatment of Neuropathic Pain Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
27 Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections Completed NCT00318591 Phase 4
28 Body Temperature in Persons With Tetraplegia When Exposed to Cold Completed NCT01822535 Phase 4 Midodrine hydrochloride
29 Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia Completed NCT00507546 Phase 4 Ramelteon;Placebo
30 Evaluation of the Nursing C-Spine (Phase IV) Completed NCT01353352 Phase 4
31 C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain Completed NCT02095197 Phase 4 Triamcinolone 80mg
32 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
33 Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD Recruiting NCT02537899 Phase 4 NeuroAiD
34 Lower Limb Function After Spinal Cord Injury Recruiting NCT02635893 Phase 4 D-Cycloserine;Placebo
35 Enhancing STDP After Spinal Cord Injury Recruiting NCT02701777 Phase 4 Seromycin;Dextromethorphan;Seromycin Placebo;Dextromethorphan Placebo
36 Denosumab Administration After Spinal Cord Injury Recruiting NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
37 The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
38 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
39 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
40 Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among SCI Recruiting NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
41 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet
42 Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia Recruiting NCT02379156 Phase 4 Midodrine Hydrochloride
43 Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity Recruiting NCT01579604 Phase 4
44 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
45 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Active, not recruiting NCT01698138 Phase 4 Onabotulinumtoxin A;Placebo
46 Once Weekly GLP-1 in Persons With Spinal Cord Injury Not yet recruiting NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
47 Treatment of Chemotherapy-related Hiccups With Baclofen Not yet recruiting NCT03778281 Phase 4 Baclofen;Methoxyclopramide
48 Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
49 Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured Terminated NCT00869427 Phase 4 vitamin C
50 Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury Withdrawn NCT02970773 Phase 4 Rivaroxaban Oral Tablet

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spinal Cord Injury:
Adipose spheroid-derived Schwann cells for the treatment of spinal cord injury
Bone marrow-derived hematopoietic stem cells for spinal cord injury
Cerecellgram-Spine, bone marrow-derived mesenchymal stem cells for treatment of chronic spinal cord injury
GRNOPC1, hESC-derived oligodendrocyte progenitor cells for spinal cord injury
HuCNS-SC, human central nervous system stem cells for neurological diseases
MultiStem, bone marrow-derived cells for neurological disorders
NSI-566, spinal cord stem cells for neurological disorders
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of spinal cord injury
Schwann cells for treatment of spinal cord injury
Umbilical cord-derived mesenchymal stem cells for treatment of spinal cord injury
Embryonic/Adult Cultured Cells Related to Spinal Cord Injury:
Schwann-like cells PMIDs: 20083105
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19364066
Bone marrow-derived mesenchymal stem cells
Oligodendrocyte progenitor-like cells PMIDs: 17996308 17253955
Human neural stem cells (HuCNS-SC�) PMIDs: 16610769
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080 22017805
Schwann cells PMIDs: 16629629 23098734 23186720
Schwann cells PMIDs: 16629629 23098734 23186720
Umbilical cord-derived mesenchymal stem cells PMIDs: 23942181

Genetic Tests for Spinal Cord Injury

Anatomical Context for Spinal Cord Injury

MalaCards organs/tissues related to Spinal Cord Injury:

42
Spinal Cord, Bone, Brain, Testes, Bone Marrow, Heart, Prostate
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Spinal Cord Injury

Articles related to Spinal Cord Injury:

(show top 50) (show all 7501)
# Title Authors Year
1
Analysis of the risk factors for tracheostomy and decannulation after traumatic cervical spinal cord injury in an aging population. ( 31076645 )
2019
2
Understanding the Changing Health Care Needs of Individuals Aging With Spinal Cord Injury. ( 30774290 )
2019
3
An epidemiological study of traumatic spinal cord injuries in the fastest aging area in Japan. ( 30733575 )
2019
4
Spinal cord injury by clip-compression induces anxiety and depression-like behaviours in female rats: The role of the inflammatory response. ( 30659938 )
2019
5
Determining Best Practices for Management of Bacteriuria in Spinal Cord Injury: Protocol for a Mixed-Methods Study. ( 30762584 )
2019
6
Pre-operative screening for asymptomatic bacteriuria and associations with post-operative outcomes in patients with spinal cord injury. ( 29578382 )
2019
7
Bladder cancer surveillance in patients with spinal cord injuries. ( 30298694 )
2019
8
Challenges to the Standardization of Trauma Data Collection in Burn, Traumatic Brain Injury, Spinal Cord Injury, and Other Trauma Populations: A Call for Common Data Elements for Acute and Longitudinal Trauma Databases. ( 31030731 )
2019
9
Cognitive, Emotional, and Physical Functioning as Predictors of Paid Employment in People With Stroke, Traumatic Brain Injury, and Spinal Cord Injury. ( 30915962 )
2019
10
Anti-muscarinic drugs increase rectal compliance and exacerbate constipation in chronic spinal cord injury : Anti-muscarinic drug effect on neurogenic bowel. ( 30804425 )
2019
11
Anal Adrenergic for Fecal Incontinence (in Spinal Cord Injury). ( 30640827 )
2019
12
Topical Oxymetazoline for Fecal Incontinence in Patients with Spinal Cord Injury: A Double-Blind Randomized Controlled Crossover Study. ( 30451757 )
2019
13
Hyperglycemia aggravates spinal cord injury through endoplasmic reticulum stress mediated neuronal apoptosis, gliosis and activation. ( 30784940 )
2019
14
Minocycline impedes mitochondrial-dependent cell death and stabilizes expression of hypoxia inducible factor-1α in spinal cord injury. ( 30899301 )
2019
15
Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets. ( 31044582 )
2019
16
A systematic review of the content and quality of clinical practice guidelines for management of the neurogenic bladder following spinal cord injury. ( 30971756 )
2019
17
Investigating neurogenic bowel in experimental spinal cord injury: where to begin? ( 30531001 )
2019
18
Identifying and Classifying Quality of Life Tools for Assessing Neurogenic Bowel Dysfunction After Spinal Cord Injury. ( 30774286 )
2019
19
Predicting osteoporosis medication receipt in Veterans with a spinal cord injury: A retrospective cohort study. ( 30888309 )
2019
20
Intermittent injection of Methylprednisolone Sodium Succinate in the treatment of Cervical Spinal Cord injury complicated with incomplete paraplegia. ( 30881412 )
2019
21
Proactive cortical control in spinal cord injury subjects with paraplegia. ( 31017041 )
2019
22
Pelvic organ prolapse and urogynecological assessment in women with spinal cord injury. ( 30097630 )
2019
23
Association of pneumonia, wound infection and sepsis with clinical outcomes after acute traumatic spinal cord injury. ( 31007137 )
2019
24
Immunotherapy With Antiprogrammed Cell Death 1 Antibody Improves Outcome in a Mouse Model of Spinal Cord Injury Followed by Staphylococcus aureus Pneumonia. ( 30303841 )
2019
25
Recurrent priapism in spinal cord injury: A case report. ( 31074709 )
2019
26
Progressive Neuromuscular Scoliosis Secondary to Spinal Cord Injury in a Young Patient Treated With Nonfusion Anterior Scoliosis Correction. ( 31068746 )
2019
27
Repeated anodal trans-spinal direct current stimulation results in long-term reduction of spasticity in mice with spinal cord injury. ( 30689208 )
2019
28
Effect of electrical stimulation on muscle atrophy and spasticity in patients with spinal cord injury - a systematic review with meta-analysis. ( 30696926 )
2019
29
Non-invasive spinal direct current simulation for spasticity therapy following spinal cord injury: mechanistic insights contributing to long-term treatment effects. ( 30820947 )
2019
30
A preclinical model of non-invasive stimulation reduces spinal cord injury initiated spasticity. ( 30945290 )
2019
31
Residual Descending Motor Pathways Influence Spasticity after Spinal Cord Injury. ( 31102289 )
2019
32
Treatment of spasticity in spinal cord injury with botulinum toxin. ( 29869974 )
2019
33
Reversible Spasticity Suppression and Locomotion Change After Pulsed Radiofrequency on the Dorsal Root Ganglia of Rats With Spinal Cord Injury. ( 30253013 )
2019
34
The Effects of Electrical Stimulation Parameters in Managing Spasticity After Spinal Cord Injury: A Systematic Review. ( 30300228 )
2019
35
Furosemide Unmasks Inhibitory Dysfunction after Spinal Cord Injury in Humans: Implications for Spasticity. ( 30417726 )
2019
36
Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury. ( 29334339 )
2019
37
Development of a novel gait analysis tool measuring center of pressure for evaluation of canine chronic thoracolumbar spinal cord injury. ( 31044646 )
2019
38
Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. ( 31045582 )
2019
39
Hyperbaric Oxygen Therapy After Acute Thoracic Spinal Cord Injury: Improvement of Locomotor Recovery in Rats: Erratum. ( 31046004 )
2019
40
Froin's syndrome after Spinal Cord Injury. ( 31048043 )
2019
41
A haemodynamic checklist to improve haemodynamic management in patients with acute spinal cord injury. ( 31048060 )
2019
42
Pigment Epithelium-Derived Factor Promotes Axon Regeneration and Functional Recovery After Spinal Cord Injury. ( 31049830 )
2019
43
Over-expression of lncRNA TCTN2 protects neurons from apoptosis by enhancing cell autophagy in spinal cord injury. ( 31050183 )
2019
44
Breastfeeding Before and After Spinal Cord Injury: A Case Report of a Mother With C6 Tetraplegia. ( 31051097 )
2019
45
Effects of FABP7 on functional recovery after spinal cord injury in adult mice. ( 31051461 )
2019
46
Sleep Complaints and Sleep Quality in Spinal Cord Injury: A Web-Based Survey. ( 31053202 )
2019
47
Risk indicators of length of acute hospital stay after traumatic spinal cord injury in South Africa: a prospective, population-based study. ( 31053775 )
2019
48
The Spinal Cord Injury Pressure Ulcer Scale (SCIPUS): an assessment of validity using Rasch analysis. ( 31053776 )
2019
49
Determining pressure injury risk on admission to inpatient spinal cord injury rehabilitation: A comparison of the Functional Independence Measure, Spinal Cord Injury Pressure Ulcer Scale, and Braden scale. ( 31054293 )
2019
50
Traumatic spinal cord injury in Victoria, 2007-2016. ( 31055854 )
2019

Variations for Spinal Cord Injury

Expression for Spinal Cord Injury

Search GEO for disease gene expression data for Spinal Cord Injury.

Pathways for Spinal Cord Injury

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 BDNF CASP3 CXCL8 IL6 LEP MAPK1
2
Show member pathways
13.52 BDNF CASP3 CXCL8 GDNF IL6 LEP
3
Show member pathways
13.36 CASP3 CXCL8 GDNF IL6 MAPK1 MMP9
4
Show member pathways
13.3 BDNF CASP3 CXCL8 IL6 MAPK1 NGFR
5
Show member pathways
13.01 BDNF CASP3 IL6 MAPK1 NGFR TNF
6
Show member pathways
12.99 CASP3 CXCL8 IL6 MAPK1 MMP9 TNF
7
Show member pathways
12.98 CASP3 IL6 MAPK1 MMP9 NGFR TNF
8
Show member pathways
12.9 CASP3 CXCL8 GDNF IL6 MAPK1 TNF
9 12.85 CASP3 CXCL8 IL6 MAPK1 MMP9 NOS2
10 12.79 BDNF CASP3 MAPK1 NGFR TNF
11
Show member pathways
12.61 IL6 MAPK1 NOS1 NOS2 TNF
12
Show member pathways
12.51 CASP3 MAPK1 NOS1 PDYN TNF
13
Show member pathways
12.5 CASP3 LEP MAPK1 NOS2
14
Show member pathways
12.49 CASP3 CXCL8 NOS1 NOS2
16
Show member pathways
12.33 CXCL8 IL6 MAPK1 NOS2 TNF
17 12.32 CASP3 MAPK1 MMP9 TNF
18
Show member pathways
12.29 CXCL8 IL6 MAPK1 TNF
19
Show member pathways
12.29 BDNF CXCL8 IL6 NGFR TNF
20
Show member pathways
12.28 CASP3 MAPK1 NOS2 TNF
21 12.28 CXCL8 IL6 MMP9 NGFR
22
Show member pathways
12.27 CASP3 CXCL8 IL6 MAPK1 MMP9 TNF
23 12.26 CASP3 IL6 MAPK1 NOS2 TNF
24
Show member pathways
12.23 CXCL8 IL6 MAPK1 NOS2 TNF
25
Show member pathways
12.21 CXCL8 IL6 NOS2 TNF
26 12.13 BDNF CASP3 MAPK1 NGFR
27
Show member pathways
12.1 BDNF CXCL8 IL6 MAPK1 NGFR
28 12.02 CASP3 IL6 MAPK1 MMP9 NOS2 TNF
29 11.97 CXCL8 IL6 MMP9 NOS2 TNF
30 11.95 AQP4 BDNF CASP3 CXCL8 IL6 TNF
31 11.93 CASP3 IL6 MAPK1 MMP9 TNF
32 11.88 CASP3 CXCL8 MAPK1
33 11.88 CASP3 CXCL8 IL6 MAPK1 TNF
34 11.87 CXCL8 IL6 TNF
35 11.85 CXCL8 IL6 MAPK1 NOS2
36
Show member pathways
11.83 CASP3 CXCL8 MAPK1
37 11.82 CXCL8 IL6 MAPK1
38 11.81 BDNF GDNF GFAP
39 11.81 CASP3 CXCL8 IL6 NOS2 TNF
40
Show member pathways
11.79 CASP3 CXCL8 TNF
41 11.77 CXCL8 MAPK1 MMP9
42 11.72 CASP3 MAPK1 MMP9 NOS2
43
Show member pathways
11.71 BDNF CASP3 NGFR RTN4R
44
Show member pathways
11.68 BDNF MAPK1 NGFR
45 11.68 CASP3 CXCL8 IL6 MMP9
46 11.66 CXCL8 IL6 MMP9 TNF
47 11.66 AQP4 BDNF CASP3 CXCL8 GDNF GFAP
48 11.65 CASP3 MMP9 PLA2G2A
49 11.62 BDNF IL6 MMP9 NOS2 TNF
50 11.59 CXCL8 IL6 MAPK1 NOS2

GO Terms for Spinal Cord Injury

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 BDNF CXCL8 IL6 KLK8 LEP MMP9
2 extracellular region GO:0005576 9.4 BDNF CXCL8 GDNF IL6 KLK8 LEP
3 membrane raft GO:0045121 9.26 CASP3 NOS1 RTN4R TNF

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 CASP3 GDNF IL6 LEP MMP9 NGFR
2 positive regulation of apoptotic process GO:0043065 9.89 CASP3 IL6 MMP9 NGFR TNF
3 response to hypoxia GO:0001666 9.85 CASP3 LEP NOS1 NOS2
4 response to lipopolysaccharide GO:0032496 9.83 CASP3 MAPK1 NOS1 NOS2
5 defense response to Gram-positive bacterium GO:0050830 9.82 IL6 PLA2G2A TNF
6 cellular response to lipopolysaccharide GO:0071222 9.81 CXCL8 IL6 NOS2 TNF
7 response to wounding GO:0009611 9.79 CASP3 GFAP KLK8
8 regulation of insulin secretion GO:0050796 9.79 LEP NOS2 TNF
9 response to glucocorticoid GO:0051384 9.78 CASP3 IL6 TNF
10 axon guidance GO:0007411 9.76 BDNF GDNF MAPK1
11 nitric oxide biosynthetic process GO:0006809 9.64 NOS1 NOS2
12 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.63 NGFR TNF
13 negative regulation of axon regeneration GO:0048681 9.63 KLK8 RTN4R
14 cytokine-mediated signaling pathway GO:0019221 9.63 CASP3 CXCL8 IL6 MMP9 NOS2 TNF
15 positive regulation of guanylate cyclase activity GO:0031284 9.62 NOS1 NOS2
16 Bergmann glial cell differentiation GO:0060020 9.6 GFAP MAPK1
17 negative regulation of neuron projection development GO:0010977 9.59 GFAP RTN4R
18 arginine catabolic process GO:0006527 9.58 NOS1 NOS2
19 positive regulation of receptor binding GO:1900122 9.57 BDNF MMP9
20 positive regulation of neuroinflammatory response GO:0150078 9.56 IL6 TNF
21 regulation of cytokine production involved in inflammatory response GO:1900015 9.54 LEP NOS2
22 neurotrophin TRK receptor signaling pathway GO:0048011 9.5 BDNF CASP3 NGFR
23 interleukin-8 secretion GO:0072606 9.48 LEP NOS2
24 peptidyl-cysteine S-nitrosylation GO:0018119 9.46 NOS1 NOS2
25 positive regulation of glial cell proliferation GO:0060252 9.43 GFAP IL6 TNF
26 prostaglandin secretion GO:0032310 9.4 LEP NOS2
27 interleukin-6 secretion GO:0072604 9.37 LEP NOS2
28 regulation of signaling receptor activity GO:0010469 9.17 BDNF CXCL8 GDNF IL6 LEP PDYN
29 negative regulation of lipid storage GO:0010888 9.13 IL6 LEP TNF

Molecular functions related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 arginine binding GO:0034618 9.26 NOS1 NOS2
2 NADPH-hemoprotein reductase activity GO:0003958 9.16 NOS1 NOS2
3 tetrahydrobiopterin binding GO:0034617 8.96 NOS1 NOS2
4 nitric-oxide synthase activity GO:0004517 8.62 NOS1 NOS2

Sources for Spinal Cord Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....